Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Nov 6;15(11):1566-1575.
doi: 10.2215/CJN.02020220. Epub 2020 Oct 6.

Combination Treatment with Sodium Nitrite and Isoquercetin on Endothelial Dysfunction among Patients with CKD: A Randomized Phase 2 Pilot Trial

Jing Chen  1   2   3   4 , L Lee Hamm  1   3 , Joshua D Bundy  2   3 , Damodar R Kumbala  5 , Shirisha Bodana  6 , Sehgal Chandra  7 , Chung-Shiuan Chen  2   3 , Charlton C Starcke  2   3 , Yajun Guo  2 , Caroline M Schaefer  2 , Eva Lustigova  2 , Erin Mahone  2   3 , Aarti M Vadalia  2   3 , Terra Livingston  2   3 , Katherine Obst  2   3 , Jesus Hernandez  1 , Syed Rizwan Bokhari  1 , Myra Kleinpeter  1 , Arnold B Alper  1 , Ivo Lukitsch  6 , Hua He  2   3 , David C Nieman  8 , Jiang He  1   2   3
Affiliations
Clinical Trial

Combination Treatment with Sodium Nitrite and Isoquercetin on Endothelial Dysfunction among Patients with CKD: A Randomized Phase 2 Pilot Trial

Jing Chen et al. Clin J Am Soc Nephrol. .

Abstract

Background and objectives: Endothelial dysfunction is common among patients with CKD. We tested the efficacy and safety of combination treatment with sodium nitrite and isoquercetin on biomarkers of endothelial dysfunction in patients with CKD.

Design, setting, participants, & measurements: This randomized, double-blind, placebo-controlled phase 2 pilot trial enrolled 70 patients with predialysis CKD. Thirty-five were randomly assigned to combination treatment with sodium nitrite (40 mg twice daily) and isoquercetin (225 mg once daily) for 12 weeks, and 35 were randomly assigned to placebo. The primary outcome was mean change in flow-mediated vasodilation over the 12-week intervention. Secondary and safety outcomes included biomarkers of endothelial dysfunction, inflammation, and oxidative stress as well as kidney function, methemoglobin, and adverse events. Intention-to-treat analysis was conducted.

Results: Baseline characteristics, including age, sex, race, cigarette smoking, history of hypertension and diabetes, use of renin-angiotensin system blockers, BP, fasting glucose, lipid profile, kidney function, urine albumin-creatinine ratio, and endothelial biomarkers, were comparable between groups. Over the 12-week intervention, flow-mediated vasodilation increased 1.1% (95% confidence interval, -0.1 to 2.3) in the treatment group and 0.3% (95% confidence interval, -0.9 to 1.5) in the placebo group, and net change was 0.8% (95% confidence interval, -0.9 to 2.5). In addition, changes in biomarkers of endothelial dysfunction (vascular adhesion molecule-1, intercellular adhesion molecule-1, E-selectin, vWf, endostatin, and asymmetric dimethylarginine), inflammation (TNF-α, IL-6, C-reactive protein, IL-1 receptor antagonist, and monocyte chemoattractant protein-1), and oxidative stress (oxidized LDL and nitrotyrosines) were not significantly different between the two groups. Furthermore, changes in eGFR, urine albumin-creatinine ratio, methemoglobin, and adverse events were not significantly different between groups.

Conclusions: This randomized phase 2 pilot trial suggests that combination treatment with sodium nitrite and isoquercetin did not significantly improve flow-mediated vasodilation or other endothelial function biomarkers but also did not increase adverse events compared with placebo among patients with CKD.

Clinical trial registry name and registration number: Nitrite, Isoquercetin, and Endothelial Dysfunction (NICE), NCT02552888.

Keywords: chronic inflammation; chronic kidney disease; endothelial dysfunction; isoquercetin; oxidative stress; sodium nitrite.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Study participant flow diagram.
See this image and copyright information in PMC

References

    1. Snyder JJ, Foley RN, Collins AJ: Prevalence of CKD in the United States: A sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 53: 218–228, 2009. - PMC - PubMed
    1. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, Chen J, He J: A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int 88: 950–957, 2015. - PMC - PubMed
    1. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS; CKD Prognosis Consortium : Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311: 2518–2531, 2014. - PMC - PubMed
    1. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium : Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375: 2073–2081, 2010. - PMC - PubMed
    1. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41: 47–55, 2003. - PubMed

Publication types

MeSH terms

Associated data